Aims Clinical trials have found differences in bleeding locations between direct oral
anticoagulants (DOAC) and vitamin K antagonists (VKA). The present study was performed …

Clinical trials described differences in anatomical localizations of bleedings between vitamin
K antagonists (VKA) and direct oral anticoagulants (DOA)[1]. RE-LY trial did not evidence …

Aims To determine the preventability of serious adverse drug reactions (ADRs) related to the
use of direct oral anticoagulants (DOACs), and to explore contributing factors to preventable …

Aims The objective was to compare major bleeding risk of direct oral anticoagulants
(DOACs; per type and dose) with vitamin K antagonists (VKAs), irrespective of indication …

Background In Italy, direct oral anticoagulant drugs (DOACs) were authorized for stroke
prevention in patients with non-valvular atrial fibrillation (NVAF) in 2013. There is conflicting …

Background The reversibility of new/novel oral anticoagulants (NOAC) is not well
understood, whereas the reversal strategies for bleeding associated with vitamin k …

Abstract Objective Direct oral anticoagulants (DOACs) were developed to avoid the
limitations of vitamin K antagonists (VKAs). DOACs are associated with a greater incidence …

Dabigatran etexilate (DE), rivaroxaban, and apixaban are nonvitamin K antagonist oral
anticoagulants (NOACs) that have been compared in clinical trials with existing …

Background and aim: Although several non-vitamin K oral anticoagulants have been
developed to prevent cardiogenic thrombosis, the status of hemorrhagic complications in the …

Background: In order to ensure safer use of non-vitamin K antagonist oral anticoagulants
(NOACs), continuously detecting unexpected adverse drug reactions (ADRs) after market …